Assessing the influence of male vaccination on cervical cancer elimination in China under different vaccination coverage scenarios: A modeling study

Le résumé fourni par la source

Cervical cancer caused by human papillomavirus (HPV) infection remains a significant public health challenge in China, where screening and HPV vaccination uptake fall well below World Health Organization's (WHO) targets. This study aimed to assess the impact of gender-neutral vaccination (GNV) on cervical cancer elimination in China at a range of vaccination coverage rates (VCRs) and screening uptake rates. Using a model to project cervical cancer incidence and cases in China over 100 years, we evaluated different vaccination strategies using either a bivalent (2vHPV) or nonavalent (9vHPV) vaccine and estimated the time taken to reach the WHO's elimination threshold of 4 cases per 100,000 women. Results showed that all GNV strategies were more effective than the corresponding girls-only strategy at preventing cervical cancer, and all 9vHPV-based strategies were more effective than the corresponding 2vHPV-based strategies, especially at lower female VCRs. At a 70% screening uptake and a female VCR of 60%, the fastest predicted disease elimination time (65 years) was achieved using GNV-9vHPV; this timeline was accelerated to 56 years at a female VCR of 90%. The time to elimination using GNV-9vHPV could be accelerated by up to 6 years by adding a catch-up vaccination program or 7 years by increasing the screening rate. These results suggest that updating the current Chinese HPV vaccination program by including males and using a nonavalent vaccine, in conjunction with efforts to increase cervical cancer screening uptake, offers the fastest route to cervical cancer elimination in China, especially while VCRs remain low.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.